1700 Journal of Medicinal Chemistry, 2005, Vol. 48, No. 6
Letters
(6) LMW antagonists for the LH receptor: Grøndahl, C. Luteinising
hormone antagonists useful for treatment of estrogen deficien-
cies, or as a contraceptive. WO 99/20223, 1999.
(13) Benzakour, O.; Kanthou, C.; Dennehy, U.; Al Haw, A.; Berg, L.
P.; Kakkar, V. V.; Cooper, D. N. Evaluation of the use of the
firefly-reporter-gene system for gene-regulation studies involving
cyclic AMP-elevating agents. Biochem. J. 1995, 309, 385-387.
(14) Manske, R. H. F.; Kulka, M. The Skraup synthesis of quinolines.
Org. React. 1953, 7, Chapter 2, pp 59-98.
(15) Shmyreva, Zh. V.; Shikhaliev, Kh. S.; Zalukaev, L. P.; Ivanov,
Y. A.; Ryabokobylko, Y. S.; Pokrovskaja, I. E. Nitration of 2,2,4-
trimethyl-4-phenyl-1,2,3,4-tetrahydroquinoline and its N-acyl
derivatives. Zh. Obshch. Khim. 1989, 59, 1391-1397.
(16) Lugovik, B. A.; Yudin, L. G.; Borodin, P. V.; Vinogradova, S. M.;
Kost, A. N. Reactions of 1,2-dihydroquinolines. III. Addition of
benzene and halobenzenes to the double bond of 2,2,4-trimethyl-
1,2-dihydroquinolines. Khim. Geterotsikl. Soedin. 1971, 7, 795-
797.
(17) Vibrational circular dichroism studies performed by BioTools
suggest that the active enantiomer has the R-configuration.
(18) Keren-Tal, I.; Dantes, A.; Sprengel, R.; Amsterdam, A. Estab-
lishment of steroidogenic granulosa cell lines expressing follicle
stimulating hormone receptors. Mol. Cell. Endocrinol. 1993, 95,
R1-R10.
(19) Rose, U.; Hanssen, R.; Kloosterboer, H. Development and
characterization of an in Vitro Ovulation Model Using Mouse
Ovarian Follicles. Biol. Reprod. 1999, 61, 503-511.
(20) Stevis, P. E.; Deecher, D. C.; Lopez, F. J.; Frail, D. E. Pharma-
cological characterization of soluble human FSH receptor ex-
tracellular domain: facilitated secretion by coexpression with
FSH. Endocrine 1999, 10, 153-160.
(21) Nakabayashi, K.; Kudo, M.; Hsueh, A. J. W.; Maruo, T. Activa-
tion of the luteinizing hormone receptor in the extracellular
domain. Mol. Cell. Endocrinol. 2003, 202, 139-144.
(22) Nakabayashi, K.; Kudo, M.; Kobilka, B.; Hsueh, A. J. W. J. Biol.
Chem. 2000, 275, 30264-30271.
(23) Gurrath, M. Peptide-binding G protein-coupled receptors: new
opportunities for drug design. Curr. Med. Chem. 2001, 8, 1605-
1648.
(24) Schwartz, T. W.; Gether, U.; Schambye, H. T.; Hjorth, S. A.
Molecular mechanism of action of non-peptide ligands for peptide
receptors. Curr. Pharm. Des. 1995, 1, 325-342.
(25) Hunyady, L.; Balla, T.; Catt, K. J. The ligand binding site of
the angiotensin AT1 receptor. Trends Pharmacol. Sci. 1996, 17,
135-140.
(7) LMW agonists for the LH receptor: (a) Gerritsma, G. G.; van
Straten, N. C. R.; Adang, A. E. P. Bicyclic heteroaromatic
compounds useful as LH agonists. WO 00/61586, 2000. (b)
Timmers, C. M.; Karstens, W. F. J. Bicyclic heteroaromatic
compounds. WO 02/24703, 2002. (c) Hanssen, R. G. J. M.;
Timmers, C. M. Thieno[2,3-d]pyrimidines with combined LH and
FSH agonistic activity. WO 03/020726, 2003. (d) Hanssen, R.
G. J. M.; Timmers, C. M.; Kelder, J. Glycine-substituted thieno-
[2,3-d]pyrimidines with combined LH and FSH agonistic activity.
WO 03/020727, 2003.
(8) LMW agonists for the FSH receptor: (a) El Tayer, N.; Reddy,
A. P.; Buckler, D.; Magar, S. FSH mimetics for the treatment of
infertility. WO 00/08015, 2000; U.S. Patent 6,235,755, 2001. (b)
Shroff, H.; Reddy, A. P.; El Tayer, N.; Brugger, N.; Jorand-
Lebrun, C. Preparation of pyrazole compounds for treatment of
infertility. WO 01/87287, 2001. (c) Guo, T.; Ho, K.; McDonald,
E.; Dolle, R. E.; Saionz, K. W.; Kultgen, S. G.; Liu, R.; Dong, G.;
Geng, P.; Adang, A. E. P.; van Straten, N. C. R. Preparation of
bisaryl derivatives having FSH receptor modulating activity. WO
02/070493, 2002. (d) Scheuerman, R. A.; Yanofsky, S. D.; Holmes,
C. P.; MacLean, D.; Ruhland, B.; Barrett, R. W.; Wrobel, J. E.;
Kao, W.; Gopalsamy, A.; Sum, F.; Hu, B.; Rogers, J. F.; Jetter,
J. W. Agonists of follicle stimulating hormone activity. WO 02/
09706, 2002.
(9) LMW antagonists for the FSH receptor: (a) Wrobel, J. E.;
Rogers, J. F.; Kao, W. 7-Amino-4-hydroxy-3-(4-methoxyphenyl-
azo)-naphthalene-2-sulfonic acid derivatives as FSH antagonists.
WO 00/58276, 2000. (b) Wrobel, J. E.; Rogers, J. F.; Green, D.
M.; Kao, W.; Jetter, J. Aryl sulfonic acids and derivatives as FSH
antagonists. WO 00/58277, 2001; U.S. Patent 6,200,963, 2000.
(c) Coats, S. J.; Hlasta, D. J.; Lantern, C. L.; Macielag, M. J.;
Rivero, R.; Fitzpatrick, L. J. Substituted aminoalkyl derivatives
as antagonists of follicle stimulating hormone. WO 01/47875,
2001. (d) Scheuerman, R. A. Yanofsky, S. D.; Holmes, C. P.;
MacLean, D.; Ruhland, B.; Barrett, R. W.; Wrobel, J. E.;
Gopalsamy, A. Antagonists of follicle stimulating hormone
activity. WO 02/09705, 2002; U.S. Patent 6,426,357, 2002.
(10) Arey, B. J.; Deecher, D. C.; Shen, E. S.; Stevis, P. E.; Meade, E.
H.; Wrobel, J.; Frail, D. E.; Lo´pez, F. J. Identification and
characterization of a selective, non-peptide follicle-stimulating
hormone receptor antagonist. Endocrinology 2002, 143, 3822-
3829.
(26) Elling, C. E.; Moeller Nielsen, S.; Schwartz, T. W. Conversion
of antagonist-binding site to metal-ion site in the tachykinin
NK-1 receptor. Nature 1995, 374, 74-77.
(11) Van Straten, N. C. R.; van Someren, R. G.; Schulz, J. Tetrahy-
droquinoline derivatives. WO 03/004028, 2003.
(12) Brasier, A.; Tate, J.; Habener, J. Optimized use of firefly
luciferase assay as a reporter gene in mammalian cell lines.
BioTechniques 1989, 7, 1116-1122.
JM049676L